Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Joint ( (JYNT) ) has issued an update.
On March 12, 2026, The Joint Corp. reported that fourth quarter 2025 revenue rose 3.1% year on year to $15.2 million, while system-wide sales fell 3.9% and same-store sales declined 3.8%, amid macro headwinds. Quarterly net income improved sharply to $1.0 million from $18,000 a year earlier, consolidated adjusted EBITDA increased 7.8% to $3.6 million, and the company repurchased 1.1 million shares for $9.0 million in the period.
For full-year 2025, revenue grew to $54.9 million from $52.2 million, consolidated net income swung to a $2.9 million profit from a $5.8 million loss, and adjusted EBITDA rose 13.9% to $13.0 million, even as system-wide sales were nearly flat and comp sales turned slightly negative. Management highlighted its “Joint 2.0” transformation, including refranchising 41 clinics in 2025, signing deals to sell additional clinics, and using share repurchases and a stronger balance sheet to support a transition to a pure-play franchisor and a more capital-efficient model.
The Joint ended 2025 with 960 clinics versus 967 a year earlier, reflecting 29 openings, 41 refranchisings and 36 closures, resulting in 885 franchised and 75 company-owned or managed clinics at year-end. The company also increased national marketing spend, improved patient attrition, and achieved faster breakeven for new clinics, positioning the business to benefit from operating leverage and a more resilient profit structure as its multi-year growth initiatives develop.
The most recent analyst rating on (JYNT) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
Spark’s Take on JYNT Stock
According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.
The score is primarily weighed down by weak and unstable recent fundamentals, including an extreme TTM revenue decline and losses, partially offset by low leverage and still-positive cash generation. Technicals are modestly improving short-term but remain weak longer-term, while valuation is demanding with a high P/E. The latest earnings call adds some support via improving EBITDA, strong cash, and buybacks, but guidance and sales trends remain mixed.
To see Spark’s full report on JYNT stock, click here.
More about Joint
The Joint Corp., listed on Nasdaq as JYNT, is a national operator, manager and franchisor of chiropractic clinics focused on providing routine and affordable chiropractic care through a largely franchised network. The company is shifting toward a capital-light, pure-play franchisor model by refranchising company-owned clinics and emphasizing system-wide royalty-driven revenue and marketing scale.
Average Trading Volume: 62,364
Technical Sentiment Signal: Strong Sell
Current Market Cap: $126.5M
Find detailed analytics on JYNT stock on TipRanks’ Stock Analysis page.